Isoptin Mite

Verapamil hydrochloride, the active ingredient in Isoptin Mite, is a calcium channel blocker presented as an oral tablet for oral use. It reduces vascular resistance and myocardial contractility, making it useful for treating hypertension, alleviating angina pectoris, and stabilising certain cardiac arrhythmias in adult patients.

GNH USA supplies Isoptin Mite as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality assurance and regulatory conformity across all markets. The company provides reliable logistics and documentation support for cross‑border procurement.

Verapamil, a calcium channel blocker, is employed in several cardiovascular disorders where modulation of calcium influx improves vascular tone and cardiac electrical stability.

- Hypertension: lowers systemic vascular resistance to help control high blood pressure. - Angina pectoris: reduces myocardial oxygen demand and improves coronary blood flow to relieve chest pain. - Cardiac arrhythmias: slows conduction through the AV node and stabilises abnormal heart rhythms such as supraventricular tachycardia.

Verapamil may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Constipation: reduced gastrointestinal motility. - Dizziness or light‑headedness: related to blood pressure lowering. - Headache: often transient during therapy initiation. - Flushing: due to peripheral vasodilation. - Peripheral edema: mild swelling of lower limbs. - Nausea: occasional gastrointestinal upset.

Serious or Rare Side Effects: - Bradycardia: markedly slow heart rate requiring medical attention. - Severe hypotension: sudden drop in blood pressure that can cause fainting. - AV block or other conduction disturbances: may necessitate discontinuation. - Allergic reactions: rash, itching, or anaphylaxis in rare cases.

Before initiating therapy, clinicians should consider several safety measures.

- Monitor blood pressure: ensure adequate control without excessive hypotension. - Assess cardiac function: evaluate for existing conduction abnormalities. - Review concomitant medications: avoid additive effects with other rate‑controlling drugs. - Use caution in hepatic impairment: dose adjustments may be needed. - Avoid abrupt discontinuation: tapering reduces risk of rebound hypertension. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Verapamil can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Beta‑blockers: combined use may cause profound bradycardia or AV block. - Digoxin: verapamil can increase digoxin serum levels, raising toxicity risk. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may markedly raise verapamil concentrations.

Moderate Interactions (Monitor Closely): - Diuretics: concurrent use can enhance hypotensive effects and electrolyte shifts. - Statins metabolised by CYP3A4 (e.g., simvastatin): may increase statin exposure and risk of myopathy.